Commercial products and programmes in obesity management

Authors

  • Z Bayat ivision of Endocrinology, Department of Internal Medicine, Helen Joseph Tertiary Hospital and University of the Witwatersrand, Johannesburg, South Africa https://orcid.org/0000-0002-0946-5934
  • S A Bhana Centre of Advanced Medicine, Waverley, Johannesburg; Chris Hani Baragwanath Academic Hospital and University of the Witwatersrand, Johannesburg, South Africa https://orcid.org/0000-0002-1753-5090
  • M Conradie-Smit Division of Endocrinology, Department of Medicine, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa
  • W May Cape Town Bariatric Clinic, Life Kingsbury Hospital, Cape Town, South Africa https://orcid.org/0009-0004-8573-224X

DOI:

https://doi.org/10.7196/SAMJ.2025.v115i9b.3702

Keywords:

Commercial, Products, Over the counter, Obesity, Guideline, South Africa

Abstract

RECOMMENDATIONS

1. For adults living with overweight or obesity, some commercial programmes exist that should achieve mild-to-moderate weight loss over the short or medium term, and a mild reduction in glycated haemoglobin values over a short term in adults with type 2 diabetes compared with usual care or education.

2. We do not recommend the use of over-the-counter commercial weight loss products for obesity management, owing to lack of evidence (Level 4, Grade D).

3. We do not suggest that commercial weight loss programmes be used for improvement in blood pressure and lipid control in adults living with obesity (Level 4, Grade D).

References

1. Chaudhry ZW, Doshi RS, Mehta AK, et al. A systematic review of commercial weight loss programmes’ effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus. Obes Rev 2016;17(8):758-769. https://doi.org/10.1111/obr.12423

2. GudzuneKA,DoshiRS,MehtaAK,etal.Efficacyofcommercialweight-lossprograms:Anupdated systematic review. Ann Intern Med 2015;162(7):501-512. https://doi.org/10.7326/m14-2238

3. O’Neil PM, Miller-Kovach K, Tuerk PW, et al. Randomised controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. Obesity (Silver Spring) 2016;24(11):2269-2277. https://doi.org/10.1002/oby.21616

4. Tucker J, Fischer T, Upjohn L, Mazzera D, Humar M. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Netw Open 2018;1(6):e183337. https://doi.org/10.1001/jamanetworkopen.2018.3337

5. Mehta AK, Doshi RS, Chaudhry ZW, et al. Benefits of commercial weight-loss programs on blood pressure and lipids: A systematic review. Prev Med 2016;90:86-99. https://doi.org/10.1016/j. ypmed.2016.06.028

6. Rose F, Henry M. The principles of nutrition, with diets and menus for reducing and gaining. In: Fishbein M, ed. Your Weight and How to Control It: A Scientific Guide by Medical Specialists and Dieticians. Garden City, NY: Doubleday, Doran & Company, 1929:23-260.

7. Geller AI, Shebab N, Weidle NJ, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med 2015;374(16):1531-1540. https://doi.org/10.1056/ NEJMsa1504267

Downloads

Published

2025-11-04

Issue

Section

Obesity Guideline

How to Cite

1.
Bayat Z, Bhana SA, Conradie-Smit M, May W. Commercial products and programmes in obesity management. S Afr Med J [Internet]. 2025 Nov. 4 [cited 2025 Nov. 12];115(10b):e3702. Available from: https://samajournals.co.za/index.php/samj/article/view/3702

Most read articles by the same author(s)

1 2 > >>